AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
From six-person startups to a $6.3 billion take-private: October's extraordinary month for Israeli tech exits
2
ServiceNow CEO says acquired Israeli startup Sweep helps it switch CRM customers in weeks, not years
3
Nice to lay off 500 employees as it struggles to navigate the AI transition
4
Israeli digital health company TailorMed acquired in $250 million deal
5
After years of delays, IDF prepares to deploy Elbit’s new Ro'em artillery systems
More news

Teva

20 stories about Teva
בניין חברת טבע כפר סבא

Teva’s transformation gains momentum as innovative drug sales rise 33%

03.11.26|Sophie Shulman
The company’s three leading proprietary medicines generated approximately $1.1 billion in quarterly revenue, prompting higher full-year forecasts. Their growth helped offset increased competition in the U.S. generics market.
בניין חברת טבע כפר סבא

Teva gets FDA green light for second long-acting schizophrenia drug

09.10.26|CTech
Weltruza follows the 2023 approval of Uzedy, extending Teva's partnership with France's Medincell as it seeks to build new sources of branded drug revenue.
בניין חברת טבע בכפר סבא לצד מנכ"ל טבע ריצ'רד פרנסיס

Teva’s comeback is real. The harder part is still ahead

22.09.26|Sophie Shulman
The company has cleaned up its balance sheet and rebuilt its pipeline, but investors are still waiting to see whether the new strategy can deliver sustained growth.
בניין חברת טבע כפר סבא

Teva moves closer to a drug for celiac disease with positive Phase 2 results

02.09.26|Sophie Shulman
The company's TEV-408 antibody met its primary endpoint in a 50-patient trial and reduced intestinal damage, inflammation and gastrointestinal symptoms. Teva is also advancing the treatment for vitiligo, potentially expanding the commercial opportunity for the same drug.
המרכז הלוגיסטי של חברת טבע בשוהם

Teva reaches its highest level since 2017 as investors embrace its transformation

23.08.26|CTech
Shares have risen about 20% in August, lifting the Israeli drugmaker's market value to $43.5 billion as innovative medicines and a growing pipeline reshape its investment story.
בניין חברת טבע כפר סבא

Teva's Israeli identity becomes a courtroom issue in U.S. price-fixing trial

13.08.26|Reuters, CTech
Humana agreed not to refer to Teva as an Israeli company during arguments or questioning after the drugmaker raised concerns about potential jury bias.
ריצרד פרנסיס נשיא ו מנכל טבע

Teva’s $40 billion comeback brings Wall Street’s biggest prize into view

30.07.26|Sophie Shulman
After years as a struggling generic-drug giant, Teva’s transformation under Richard Francis has pushed its valuation above $40 billion and raised the possibility of joining the S&P 500.
ריצרד פרנסיס נשיא ו מנכל טבע

Teva posts strong revenue growth as branded drugs surpass $1 billion, despite acquisition-driven loss

29.07.26|Sophie Shulman
Revenue beats expectations and outlook improves, even as the Emalex acquisition pushes the company to a quarterly loss.
ריצרד פרנסיס נשיא ו מנכל טבע

Teva’s search for a TAPI buyer ends in more job cuts

11.06.26|Sophie Shulman
Neot Hovav facility faces another round of reductions as sale prospects fade.
בניין חברת טבע כפר סבא

Teva to cut 250 jobs in API division as sale talks stall

10.06.26|Sophie Shulman
Pharmaceutical giant restructures raw materials unit amid stalled revenues and strategic review. 
בניין חברת טבע כפר סבא

The deal that signals Teva is back

30.04.26|Sophie Shulman
A calculated biotech acquisition and strong earnings revive confidence in the pharma giant.
ריצרד פרנסיס נשיא ו מנכל טבע

Teva beats estimates but cuts profit outlook after Emalex deal

29.04.26|Sophie Shulman
Strong Austedo growth offsets generics weakness as margins face acquisition-related pressure.
המרכז הלוגיסטי של חברת טבע בשוהם

Teva to acquire Emalex in deal worth up to $900 million

29.04.26|Sophie Shulman, CTech
The move strengthens Teva's pipeline with Tourette’s treatment and supports its “Beyond Growth” strategy.
ריצ'רד פרנסיס מפגש העיתונאים

Teva CEO cashes in $30 million in shares in two weeks

08.03.26|Sophie Shulman
Richard Francis sells stock after Teva’s 110% rally over the past year.
ריצרד פרנסיס נשיא ו מנכל טבע

Teva secures $400 million from Blackstone to advance flagship IBD drug

04.03.26|Sophie Shulman
The funding bolsters late-stage development of Duvakitug as the company races toward a $30 billion market.
נשיא ומנכ"ל טבע ריצ'רד פרנסיס

After a threefold rally, Teva faces its next test

29.01.26|Sophie Shulman
Innovative drugs surge, but 2026 forecasts revive investor doubts.
המרכז הלוגיסטי של חברת טבע בשוהם

Teva’s 2026 forecast disappoints despite strong finish to 2025

28.01.26|Sophie Shulman
Lower revenue guidance overshadows rapid growth in branded drugs.
המרכז הלוגיסטי של חברת טבע בשוהם

Teva bets on vitiligo drug in deal worth up to $500 million

12.01.26|Sophie Shulman
Agreement with Royalty Pharma underscores shift toward branded medicines.
המטה הגלובלי של חברת טבע בת"א

Teva’s branded drugs spark investor optimism

06.11.25|Sophie Shulman
The pharmaceutical company recorded its 11th consecutive quarter of growth, with revenue of $4.5 billion, thanks to sales of its brand-name drugs Austedo, Ajovy and Uzedy, which jumped 33%.
ריצ'רד פרנסיס מפגש העיתונאים

Teva shares soar on strong third-quarter performance

05.11.25|Sophie Shulman
Revenue climbs 3% to $4.5 billion, exceeding analysts’ expectations.
More Articles